EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

Joyce F Liu iD, Stéphanie Gaillard iD, Andrea E Wahner Hendrickson iD, Oladapo Yeku iD, Elisabeth Diver, Camille Gunderson Jackson, Rebecca Arend, Elena Ratner, Vivek Samnotra, Divya Gupta, Jon Chung, Hailei Zhang und 6 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00693 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Joyce F Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Bevacizumab, Indazoles, Piperidines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To report the results of OPAL (ClinicalTrials.gov identifier: NCT03574779 ) cohort A, a single-arm substudy of niraparib plus dostarlimab and bevacizumab for the treatment of advanced, platinum-resistant ovarian cancer (PROC). METHODS Participants with PROC who received 1-2 previous lines of therapy were treated with niraparib (200 or 300 mg once daily), dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), and bevacizumab (15 mg/kg once every 3 weeks). The primary end point was investigator-assessed objective response rate (ORR) per RECIST v1.1. Safety was also assessed. Exploratory biomarker end points included evaluation of changes in the tumor molecular profile and microenvironment using baseline and on-treatment tumor samples. RESULTS Of 41 enrolled participants (median age, 66.0 years [range, 37-83 years]), 9.8% had tumors that were BRCA-mutated, 19.5% were homologous recombination (HR)–deficient, and 17.1% were HR repair (HRR)–mutated. As of the cutoff date, all participants discontinued treatment. The ORR was 17.1% (80% CI, 9.8 to 27.0), including one complete response (2.4%); the disease control rate was 73.2% (80% CI, 62.3 to 82.2). Two participants withdrew before first postbaseline scan because of adverse events (AEs). Grade ≥3 treatment-emergent AEs were reported in 92.7% of participants, with the most common being hypertension (26.8%). Response was not correlated with BRCA, HRR, HR deficiency (HRD), or PD-L1 status. Changes suggesting immune activation were observed in on-treatment samples after triplet therapy. CONCLUSION Results demonstrated modest activity of niraparib, dostarlimab, and bevacizumab in participants with PROC, many of whom had prognostic factors for poor treatment response. Most participants with response were bevacizumab-naïve. No association was found with HRD, BRCA, or PD-L1 status. AEs were consistent with previous monotherapy reports, except that hypertension was reported more frequently.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsBevacizumabIndazolesPiperidinesDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAgedAdultAged, 80 and overAntibodies, Monoclonal, HumanizedCohort Studies

Substanzen

BevacizumabIndazolesPiperidinesAntibodies, Monoclonal, Humanizedniraparibdostarlimab

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA.
  • Johns Hopkins University, Baltimore, MD.
  • Mayo Clinic, Rochester, MN.
  • Massachusetts General Cancer Center, Boston, MA.
  • Stanford Women's Cancer Center, Palo Alto, CA.
  • Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

ORCID-Profile: Joyce F Liu, Stéphanie Gaillard, Andrea E Wahner Hendrickson, Oladapo Yeku, Gottfried E Konecny

Förderung

  • NCATS NIH HHS

Zitieren

APA

Liu, J. F., Gaillard, S., Wahner Hendrickson, A. E., Yeku, O., Diver, E., Gunderson Jackson, C., Arend, R., Ratner, E., Samnotra, V., Gupta, D., Chung, J., Zhang, H., Compton, N., Baines, A., Bacqué, E., Liu, X., Felicetti, B., & Konecny, G. E. (2024). Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology. https://doi.org/10.1200/po.23.00693

Vancouver

Liu JF, Gaillard S, Wahner Hendrickson AE, Yeku O, Diver E, Gunderson Jackson C, et al. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology. 2024. doi:10.1200/po.23.00693

BibTeX
@article{Liu2024,
  author = {Liu, Joyce F and Gaillard, Stéphanie and Wahner Hendrickson, Andrea E and Yeku, Oladapo and Diver, Elisabeth and Gunderson Jackson, Camille and Arend, Rebecca and Ratner, Elena and Samnotra, Vivek and Gupta, Divya and Chung, Jon and Zhang, Hailei and Compton, Natalie and Baines, Amanda and Bacqué, Emeline and Liu, Xiaohong and Felicetti, Brunella and Konecny, Gottfried E},
  title = {Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00693}
}
Kostenlos starten →